Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.

The European respiratory journal - 1 Feb 2022

Franciosi Alessandro N, Fraughen Daniel, Carroll Tomás P, McElvaney Noel G

Abstract excerpt

Alpha-1 antitrypsin deficiency (AATD) is the only readily identifiable monogenic cause of COPD. To date the only condition-specific treatment for AATD-associated COPD is weekly administration of intravenous plasma-purified human alpha-1 antitrypsin (IV-AAT). Uncertainties regarding which AATD genotypes should benefit from IV-AAT persist. IV-AAT is costly and involves weekly administration of a plasma product....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation and Thrombosis Mechanisms

Share to Genotype

Share to Peptidase Inhibition and Analysis

Share to Protease and Inhibitor Mechanisms

Share to Pulmonary Disease, Chronic Obstructive

Share to Risk Assessment

Source

Identifiers

PMID: 34172471
DOI: 10.1183/13993003.01410-2021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.PMID 34172471Read ↗

Alpha-1 antitrypsin deficiency: whom to test, whom to treat?Semantic proximity Read ↗

Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency.Semantic proximity Read ↗

Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.Semantic proximity Read ↗

α1-Antitrypsin deficiency and chronic respiratory disorders.Semantic proximity Read ↗

Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency: outstanding questions and future directionsSemantic proximity Read ↗

Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency.Semantic proximity Read ↗

A Review of α1-Antitrypsin DeficiencySemantic proximity Read ↗

Role of alpha-1 antitrypsin in human health and disease.Semantic proximity Read ↗

Pulmonary manifestations of alpha 1 antitrypsin deficiency.Semantic proximity Read ↗

SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ.Semantic proximity Read ↗

COPD: new lessons from alpha1-antitrypsin deficiency?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.